- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07831044
Analysis of Cerebrospinal Fluid Dynamics in Normal Pressure Hydrocephalus
Analysis of Cerebrospinal Fluid Dynamics in Patients With Normal Pressure Hydrocephalus Using Magnetic Resonance Imaging
This study aims to evaluate whether phase-contrast magnetic resonance imaging (MRI)-based cerebrospinal fluid (CSF) flow dynamics can improve the diagnosis and prognostic assessment of normal pressure hydrocephalus (NPH). In addition, the study investigates how changes in CSF flow parameters before and after CSF diversion procedures are associated with clinical improvement.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eungseok Oh
- Phone Number: 82-42-280-7800
- Email: doctor_oh@daum.net
Study Locations
-
-
Jung-gu
-
Daejeon, Jung-gu, South Korea, 35015
- Recruiting
- Chungnam National University Hospital
-
Contact:
- Eungseok Oh
- Phone Number: 82-42-280-7800
- Email: doctor_oh@daum.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients presenting with clinical symptoms consistent with normal pressure hydrocephalus (presence of gait disturbance accompanied by at least one of the following: cognitive impairment or urinary dysfunction)
- Evans' ratio ≥ 0.3 on brain MRI
Exclusion Criteria:
- Patients who cannot undergo CSF drainage due to structural abnormalities of the lumbar spine
- Contraindications to lumbar puncture and CSF drainage (e.g., local infection at the puncture site, suspected elevated intracranial pressure, platelet count < 40,000/µL, or coagulopathy)
- Coexisting neurological disorders that can also cause gait disturbance, such as Parkinson's disease, atypical parkinsonian syndromes, or vascular parkinsonism
- Contraindications to MRI (e.g., presence of cardiac pacemakers, implantable defibrillators, or other non-MRI-compatible implantable medical devices)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cerebrospinal fluid drainge
|
Cerebrospinal fluid drainge |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Cerebrospinal Fluid Flow Velocity (cm/s) at 30 Minutes Post-Procedure
Time Frame: Baseline (Pre-intervention) and 30 minutes post-intervention
|
Assessment of cerebrospinal fluid flow parameters before and after the procedure. |
Baseline (Pre-intervention) and 30 minutes post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in 10-Meter Walk Test (10MWT) Time at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
Completion time during the 10-meter walk test, measured in seconds. |
Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
|
Change from Baseline in 10-Meter Walk Test Step Count at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
Number of steps taken during the 10-meter walk test, measured in steps. |
Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
|
Change from Baseline in Timed Up and Go (TUG) Test Time at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
Completion time during the 3-meter TUG test, measured in seconds. |
Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
|
Change from Baseline in Cognitive Timed Up and Go (Cognitive TUG) Test Time at 6 Hours and 24 Hours Post-Procedure
Time Frame: Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
Completion time during the 3-meter Cognitive TUG test while performing a dual task, measured in seconds. |
Baseline, 6 hours post-procedure, and 24 hours post-procedure
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Sharma AK, Gaikwad S, Gupta V, Garg A, Mishra NK. Measurement of peak CSF flow velocity at cerebral aqueduct, before and after lumbar CSF drainage, by use of phase-contrast MRI: utility in the management of idiopathic normal pressure hydrocephalus. Clin Neurol Neurosurg. 2008 Apr;110(4):363-8. doi: 10.1016/j.clineuro.2007.12.021. Epub 2008 Feb 20.
- Al-Zain FT, Rademacher G, Meier U, Mutze S, Lemcke J. The role of cerebrospinal fluid flow study using phase contrast MR imaging in diagnosing idiopathic normal pressure hydrocephalus. Acta Neurochir Suppl. 2008;102:119-23. doi: 10.1007/978-3-211-85578-2_24.
- Shanks J, Markenroth Bloch K, Laurell K, Cesarini KG, Fahlstrom M, Larsson EM, Virhammar J. Aqueductal CSF Stroke Volume Is Increased in Patients with Idiopathic Normal Pressure Hydrocephalus and Decreases after Shunt Surgery. AJNR Am J Neuroradiol. 2019 Mar;40(3):453-459. doi: 10.3174/ajnr.A5972. Epub 2019 Feb 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025-06-077
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.